Sun Pharma extends rally on EIR from USFDA for Halol facility

The stock was up 4% to Rs 561 on BSE in early morning trade, extending its past five days 14% rally, after the company announced the resolution of regulatory compliance issues at Halol plant.

Sun Pharmaceutical Industries was up 4% to Rs 561 on BSE in early morning trade, extending its past five days 14% rally, after the company announced the resolution of regulatory compliance issues at Halol plant.

In a stock exchange notification on Tuesday after market hours, Sun Pharma said it has received the Establishment Inspection Report (EIR) from the USFDA for the inspection conducted at its Halol plant during February 12-23.

The agency concluded that the inspection is now closed and the issues contained in the warning letter issued in December 2015 have been addressed.

Commenting on the